CenterPoint Energy heads into the final week of August with a notable divergence: short sellers are rapidly unwinding positions even as the stock slides and analysts cut price targets.
The short-side retreat is the week's clearest signal. Short interest dropped 11.4% over the past week to 6.3% of free float — roughly 41 million shares — its lowest reading in the 30-day window tracked here. A sharp 8.8% single-day drop on August 25 stands out. That kind of rapid unwinding points to short sellers covering into weakness rather than adding conviction to the downside. The lending market confirms there's no pressure forcing their hand: borrow availability is running at a comfortable 470%, well above the 52-week trough of 358%, and cost to borrow is a negligible 0.51%. The ORTEX short score has dropped from 58.2 on August 19 to 53.1 now — still in moderate territory but moving in the right direction for bulls.
Options positioning tells a slightly more cautious story. The put/call ratio has crept up to 0.23, about 1.3 standard deviations above its 20-day average of 0.20. That's not an alarm-level reading — the 52-week high sits at 0.68 — but it does suggest a mild uptick in hedging demand as the stock falls. CNP is down 4% on the week and 12.6% over the past month, closing at $38.93 on Tuesday. Peers moved in a similar direction: fell 3.9% on the week, dropped 3.5%, and shed 3.3%, suggesting the weakness reflects a broader sector rotation rather than a CNP-specific problem.
The Street has spent the past month in target-trimming mode, though no one is downgrading. Morgan Stanley cut its target to $39 on August 21 while holding Equal-Weight — notable because that puts the target within pennies of the current price, offering virtually no implied upside. Evercore ISI and Truist Securities also lowered targets in August, to $43 and $46 respectively, while keeping neutral-to-positive ratings. The consensus mean target remains $45.75, implying roughly 17% upside from current levels, but the direction of travel is clearly downward. The analyst recommendation factor score ranks in the 91st percentile across the market — suggesting the Street is unusually constructive in aggregate — but the steady target erosion signals growing caution about the pace of value realisation. On valuation, the price-to-earnings multiple has compressed roughly 1.3 points over 30 days to 20.2x, tracking the stock lower.
The bull case rests on CNP's 8% year-over-year commercial and industrial load growth in Houston and a funds-from-operations-to-debt ratio of 14.1% — within the company's own 14%-15% target range. Bears point to slowing Houston load growth, the pending sale of the Ohio gas utility, and credit agencies Moody's and S&P maintaining negative outlooks. Both sides of that debate remain live, and the next scheduled earnings release is October 28 — still two months away. The most recent print on July 28 delivered a 2.5% one-day decline and a 5.5% five-day decline, so the stock has a recent habit of disappointing on the day.
What to watch: whether the pace of analyst target reductions stabilises at current levels or accelerates toward the $39 floor that Morgan Stanley now occupies, and whether the short-covering trend continues even as the stock tests its lowest levels since the spring.
See the live data behind this article on ORTEX.
Open CNP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
